Genmab Provided Earnings Guidance for Year 2022. For the year, company expects its revenue to be in the range of DKK 13,500 million DKK 14,500 million, an increase to the previous guidance of DKK 12,000 million DKK 13,000 million and expects operating profit to be in the range of DKK 5,100 million DKK 6,500 million, an increase to the previous guidance of DKK 3,800 million DKK 5,400 million, driven primarily by the items described above.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,084 DKK | -1.98% | +2.51% | -3.29% |
Mar. 18 | Genmab Completes Share Buyback Program | MT |
Mar. 15 | Genmab to Repurchase Up to $511 Million Shares | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.29% | 19.68B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B | |
-6.78% | 10.2B |
- Stock
- Equities
- Stock Genmab A/S - Nasdaq Copenhagen
- News Genmab A/S
- Genmab Provides Earnings Guidance for Year 2022